Form 8-K - Current report:
SEC Accession No. 0001104659-22-128671
Filing Date
2022-12-20
Accepted
2022-12-20 16:30:31
Documents
14
Period of Report
2022-12-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2233150d1_8k.htm   iXBRL 8-K 31566
2 EXHIBIT 10.1 tm2233150d1_ex10-1.htm EX-10.1 12265
3 EXHIBIT 10.2 tm2233150d1_ex10-2.htm EX-10.2 15752
  Complete submission text file 0001104659-22-128671.txt   240815

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA syn-20221215.xsd EX-101.SCH 3060
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20221215_lab.xml EX-101.LAB 34476
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20221215_pre.xml EX-101.PRE 22614
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2233150d1_8k_htm.xml XML 3614
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 221475208
SIC: 2834 Pharmaceutical Preparations